Author

Nuttarak Sasipong

Observed names: N. Sasipong, Sasipong, Nuttarak

Observed institutions: Chulalongkorn University, Heidelberg University, University Hospital Heidelberg

OpenAlex ID: A5043599486

Low‐Dose Emicizumab Versus Low‐/Intermediate‐Dose Factor VIII Secondary Prophylaxis for Noninhibitor Haemophilia A Patients With Severe Bleeding Phenotype

2024 · Nuchanun Kessakorn, Itsaraet Gosriwatana, et al. · Haemophilia · 12

Ligand-activated RXFP1 gene therapy ameliorates pressure overload-induced cardiac dysfunction

2021 · Nuttarak Sasipong, Philipp Schlegel, et al. · Molecular Therapy · 10

Cardiomyocyte-specific RXFP1 overexpression protects against pressure overload-induced cardiac dysfunction independently of relaxin

2024 · J. Wingert, E. Meinhardt, et al. · Biochemical Pharmacology · 3

P-754. Retrospective Study of Necrotizing Fasciitis: A Review of 99 Cases in a Tertiary Care Center in Eastern Thailand from 2022 to 2023

2025 · Tuntanut Lohawatcharagul, Supaschin Jamjittrong, et al. · Open Forum Infectious Diseases · 1

P-1958. Impact of COVID-19 on Acute Diverticulitis: Evidence of United States Hospitals in 2020

2025 · Thanathip Suenghataiphorn, Tuntanut Lohawatcharagul, et al. · Open Forum Infectious Diseases

Targeted overexpression of relaxin receptor 1 (RXFP1) with chronic administration of relaxin as a novel inotropic approach for heart failure treatment

2020 · Sasipong, Nuttarak · heiDOK (Heidelberg University)

Works count: 6

Citation count: 26

H-index: 3

I10-index: 2